Merck KGaA and Remepy join forces to develop combo drug-digital therapies
Merck KGaA has inked a collaboration deal with Israeli-US startup, Remepy, to explore the therapeutic potential of combination drug and …
Post
-
-
Seaport and Hemab target $180m IPOs as biotech listings accumulate
Seaport Therapeutics and Hemab Therapeutics have both outlined pricings for their respective initial public offerings (IPOs), adding to an already …
-
BioMarin acquires Amicus Therapeutics for $4.8bn
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal …
-
FDA approves AstraZeneca’s Saphnelo for SLE
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for the subcutaneous self-administration of Saphnelo (anifrolumab-fnia) using …
-
Early detection of bowel Cancer in the UK represents success of screening program
Bowel cancer, also known as colorectal cancer, is the second most lethal cancer after lung cancer, with the highest incidence …
-
Eli Lilly outlays $2.3bn to acquire blood cancer specialist Ajax Therapeutics
Eli Lilly has added yet another string to its M&A bow of 2026 after agreeing to acquire cancer specialist Ajax …
-
Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a growing shift …
-
Pharma Meets AI Conference 2026: AI governance shifts to embedded practice
At the Pharma Meets AI conference in Barcelona, Spain, in April 2026, discussions around AI governance highlighted a clear shift …
-
ESCMID Global 2026: Pritelivir excels in immunocompromised refractory HSV patients
At the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026 conference, Phase III data for Aicuris’s pritelivir, …
-
MFN changing the rules of the game for the Nordic countries
Innovative pharmaceutical trade associations across the Nordic region have reacted with vigilance to a recent report by GlobalData that highlighted …
-
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU) …
-
UK biotech could be bound for recovery, BIA report reveals
New data debuted by the UK’s BioIndustry Association (BIA) has hinted towards the recovery of the British biotech financing market, …
-
Sun Pharma to acquire Organon for $11.75bn
Sun Pharmaceutical Industries has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash, …
-
The slow march of clinical biomarkers to become surrogate endpoints
Clinicians have often pushed for certain biomarkers to move from serving a purely informative role in clinical trials to becoming …
-
AAN 2026: Tavapadon post-hoc analysis strengthens its D1/D5 agonist pitch
On 21 April, at the 2026 American Academy of Neurology (AAN) meeting, AbbVie presented new results from its post-hoc analysis …
